Dingxie Liu

发表

Functional Characterization of the T1799-1801del and G1799-1816ins BRAF Mutations in Papillary Thyroid Cancer

P. Hou, M. Xing, Dingxie Liu, 2007, Cell cycle.

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

G. Ning, M. Xing, Dingxie Liu, 2011, The Journal of clinical endocrinology and metabolism.

Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications

R. Wahl, P. Hou, M. Xing, 2009, PloS one.

The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression.

M. Xing, Dingxie Liu, Jin Ye, 2014, The Journal of clinical endocrinology and metabolism.

Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.

P. Hou, M. Xing, Dingxie Liu, 2011, Endocrine-related cancer.

Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.

M. Xing, Dingxie Liu, M. Xing, 2008, Thyroid : official journal of the American Thyroid Association.

AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer

Dingxie Liu, 2020, Cellular Oncology.

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

A. El‐Naggar, J. Bishop, S. Pai, 2014 .

Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer

A. El‐Naggar, P. Hou, Shuiying Hu, 2007, Clinical Cancer Research.

Genetic Alterations andTheir Relationship in the Phosphatidylinositol 3-Kinase / Akt Pathway inThyroid Cancer

A. El‐Naggar, P. Hou, Shuiying Hu, 2007 .

Association of the T 1799 A BRAF mutation with tumor extrathyroidal invasion , higher peripheral platelet counts , and over-expression of platelet-derived growth factor-B in papillary thyroid cancer

P. Hou, M. Xing, Dingxie Liu, 2008 .

Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.

P. Hou, M. Xing, Dingxie Liu, 2008, Endocrine-related cancer.

BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.

M. Xing, Dingxie Liu, Zhi Liu, 2007, The Journal of clinical endocrinology and metabolism.

IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer

A. El‐Naggar, V. Vasko, M. Xing, 2010, Clinical Cancer Research.

Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer

Dingxie Liu, P. Hofman, 2022, Cellular Oncology.

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer

M. Xing, Dingxie Liu, A. K. Murugan, 2013, Endocrine-related cancer.

Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors.

P. Hou, Biju Joseph, M. Xing, 2007, The Journal of clinical endocrinology and metabolism.

Lack of Mutations in the Thyroid Hormone Receptor (TR) α and β Genes but Frequent Hypermethylation of the TRβ Gene in Differentiated Thyroid Tumors

P. Hou, Biju Joseph, Dingxie Liu, 2007 .

Single Nucleotide Polymorphism rs17849071 G/T in the PIK3CA Gene Is Inversely Associated with Follicular Thyroid Cancer and PIK3CA Amplification

P. Ladenson, B. Trink, M. Xing, 2012, PloS one.

An Anaplastic Lymphoma Kinase Pathway Signature is associated with Cell De-differentiation, Neoadjuvant Response and Recurrence Risk in Breast Cancer

Yong Wu, Dingxie Liu, 2019 .

Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Dingxie Liu, J. Benzaquen, P. Hofman, 2022, Cancers.

The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.

M. Xing, Dingxie Liu, Ruixin Liu, 2012, The Journal of clinical endocrinology and metabolism.

The Akt Inhibitor MK 2206 Synergizes , but Perifosine Antagonizes , the BRAFV 600 E Inhibitor PLX 4032 and the MEK 1 / 2 Inhibitor AZD 6244 in the Inhibition of Thyroid Cancer Cells

M. Xing, Dingxie Liu, Ruixin Liu, 2012 .

Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer

J. Califano, W. Westra, M. Zeiger, 2006, International journal of cancer.

The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells

P. Hou, M. Xing, Dingxie Liu, 2012, Cell cycle.

High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.

Wei Wang, Bingyin Shi, Peng Hou, 2007, The Journal of clinical endocrinology and metabolism.

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

G. Ning, M. Xing, Dingxie Liu, 2011, The Journal of clinical endocrinology and metabolism.

BRAF mutation‐selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic‐potentiated synergism with the mTOR inhibitor temsirolimus

B. Trink, M. Xing, Dingxie Liu, 2010, International journal of cancer.

Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.

Peng Hou, Guojun Wu, P. Hou, 2009, Cancer research.

Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer.

P. Ladenson, A. Carvalho, D. Sidransky, 2006, The Journal of clinical endocrinology and metabolism.

Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant

P. Hou, Shuiying Hu, M. Xing, 2007, Clinical Cancer Research.

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

J. Bishop, S. Pai, M. Xing, 2013, Endocrine-related cancer.

Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer.

M. Xing, Dingxie Liu, Ermal Bojdani, 2013, Journal of the National Cancer Institute.

REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer

Xiaopei Shen, M. Xing, Dingxie Liu, 2015, Oncotarget.

Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis

Dingxie Liu, 2019, Cellular Oncology.

Gene signatures of estrogen and progesterone receptor pathways predict the prognosis of colorectal cancer

Dingxie Liu, 2016, The FEBS journal.

Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells

M. Xing, Dingxie Liu, Xuan Liu, 2014, Cell cycle.

Association of an anaplastic lymphoma kinase pathway signature with cell de‐differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer

Yong Wu, Dingxie Liu, 2020, Cancer communications.

Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation.

M. Xing, Dingxie Liu, J. Tauler, 2010, Neoplasia.

Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.

A. Dackiw, M. Xing, Dingxie Liu, 2007, The Journal of clinical endocrinology and metabolism.

Experimental infection of nonenveloped DNA virus (TTV) in Rhesus monkey

Dingxie Liu, K. Luo, H. Xiao, 2000, Journal of medical virology.

Novel variants related to TT virus distributed widely in China *

Zhihua Liu, Dingxie Liu, Hong Xiao, 2002, Journal of medical virology.

Correction: OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation

Jun Yu, J. Rhim, D. Sidransky, 2008, PLoS ONE.

OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation

Jun Yu, J. Rhim, D. Sidransky, 2008, PloS one.

Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers

Dingxie Liu, 2020, Breast Cancer Research and Treatment.

Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma.

M. Xing, Dingxie Liu, Xuan Liu, 2012, Biochemical and biophysical research communications.

BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.

Dingxie Liu, Kehua Zhou, 2020, Clinical breast cancer.

Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis

J. Vadgama, Yong Wu, Dingxie Liu, 2021, International journal of biological sciences.

A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes‐Associated Breast Cancer

Jieqing Li, Q. Hao, W. Cao, 2022, Advanced science.

The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene

Dingxie Liu, P. Hou, D. Liu, 2007, Leukemia.

Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis

Dingxie Liu, 2019, Cellular Oncology.

Letter re: uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors.

P. Ladenson, Dingxie Liu, E. Mambo, 2005, The Journal of clinical endocrinology and metabolism.